Lead Product(s) : LAE120
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Laekna's LAE120 IND Approved by FDA for Advanced Solid Tumors
Details : LAE120 is an novel USP1 inhibitor drug candidate, being investigated for the treatment of advanced solid tumors.
Product Name : LAE120
Product Type : Antibody
Upfront Cash : Inapplicable
March 03, 2025
Lead Product(s) : LAE120
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Laekna Gets FDA Approval for Phase III Protocol of LAE002 Plus LAE001 in Prostate Cancer
Details : LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 inhibitor) is being developed in patients with mCRPC following standard of care (SOC) treatment.
Product Name : LAE001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2024
Lead Product(s) : Afuresertib,Sintilimab,Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LAE002 (Afuresertib) a potent next-generation small molecule pan-AKT kinase inhibitor in combination with sintilimab and chemotherapy, targets patients with specific solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors.
Product Name : LAE002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2022
Lead Product(s) : Afuresertib,Sintilimab,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Afuresertib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Afuresertib is a clinically proven, highly potent small-molecule pan-AKT inhibitor. Afuresertib is being studied in global clinical studies in four different cancers including ovarian cancer, prostate cancer, triple-negative breast cancer, and HR+/HER2- ...
Product Name : LAE002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2021
Lead Product(s) : Afuresertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LAE001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Laekna Therapeutics Will Present Two Clinical Study Results in ESMO 2021
Details : It is a novel, potent, non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 (aldosterone synthase) that blocks both androgen and aldosterone synthesis, Therefore, unlike abiraterone acetate, LAE001 does not need a co-medication of prednisone.
Product Name : LAE001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2021
Lead Product(s) : LAE001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable